“Alzheimer’s Disease Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Alzheimer’s Disease Market.
The Alzheimer’s Disease Pipeline report embraces in-depth commercial, regulatory, and Alzheimer’s Disease clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Alzheimer’s Disease drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Alzheimer’s Disease Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for Alzheimer’s Disease treatment and the aggregate therapies developed by major pharma companies.
-
It accesses the different Alzheimer’s Disease therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the major Alzheimer’s Disease companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the Alzheimer’s Disease drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Alzheimer’s Disease therapeutic market.
Alzheimer’s Disease Therapeutics Landscape
Approximately 150+ key companies are actively engaged in developing therapies for Alzheimer’s Disease, highlighting the significant efforts within the pharmaceutical and biotechnology industries to address this complex neurological condition. Among these companies, those with drug candidates in the most advanced stage, specifically Phase III clinical trials, include KeifeRx. These companies represent a diverse range of approaches and technologies aimed at tackling Alzheimer’s Disease, offering hope for patients, caregivers, and healthcare professionals. As research progresses and clinical trials advance, the potential for innovative therapies to positively impact the lives of those affected by Alzheimer’s Disease continues to grow.
Alzheimer’s Disease Companies Actively Working in the Therapeutic Market Include:
Some of the key companies in the Alzheimer’s Disease Therapeutics Market include Cassava Sciences, KeifeRx, AB Science, Eli Lilly and Company, BioVie Inc., AriBio Co., Ltd., Novo Nordisk, Alector Inc., Longeveron Inc., Cognition Therapeutics, True Binding, Inc., AbbVie, and Shanghai Hengrui Pharmaceutical Co., Ltd. and others.
Emerging and Marketed Alzheimer’s Disease Drugs Covered in the Report Include:
-
Nilotinib: KeifeRx
-
AR1001: AriBio Co., Ltd.
-
LY3372689: Eli Lilly & Co.
And Many Others
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Alzheimer’s Disease Companies Working in the Market:
https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight
Analysis of Emerging Alzheimer’s Disease Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued and inactive candidates
Route of Administration
Alzheimer’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Oral
-
Parenteral
-
Intravenous
-
Subcutaneous
-
Topical.
Molecule Type
Products have been categorized under various Molecule types such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Learn How the Alzheimer’s Disease Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @
https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Alzheimer’s Disease Treatment Patterns
4. Alzheimer’s Disease – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Alzheimer’s Disease Late Stage Products (Phase-III)
7. Alzheimer’s Disease Mid-Stage Products (Phase-II)
8. Alzheimer’s Disease Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Alzheimer’s Disease Discontinued Products
13. Alzheimer’s Disease Product Profiles
14. Major Alzheimer’s Disease Companies in the Market
15. Key Products in the Alzheimer’s Disease Therapeutics Segment
16. Dormant and Discontinued Products
17. Alzheimer’s Disease Unmet Needs
18. Alzheimer’s Disease Future Perspectives
19. Alzheimer’s Disease Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
Acute On Chronic Liver Failure (ACLF) Market
“Acute On Chronic Liver Failure (ACLF) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Acute On Chronic Liver Failure market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Acute On Chronic Liver Failure market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices